Agenus (NASDAQ:AGEN) Posts Earnings Results, Beats Estimates By $0.58 EPS

Agenus (NASDAQ:AGEN) issued its quarterly earnings results on Monday. The biotechnology company reported ($1.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.61) by $0.58, Zacks reports. The company had revenue of $24.07 million during the quarter, compared to analysts’ expectations of $26.38 million.

Agenus Price Performance

AGEN opened at $3.38 on Wednesday. The stock has a 50-day moving average price of $2.17 and a 200-day moving average price of $2.91. The firm has a market cap of $71.56 million, a PE ratio of -0.30 and a beta of 1.48. Agenus has a 1 year low of $1.38 and a 1 year high of $19.69.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on AGEN. B. Riley restated a “buy” rating on shares of Agenus in a research report on Monday, April 21st. HC Wainwright reiterated a “neutral” rating on shares of Agenus in a report on Tuesday. Robert W. Baird lifted their price target on shares of Agenus from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Tuesday. Finally, StockNews.com upgraded shares of Agenus from a “sell” rating to a “hold” rating in a report on Friday, March 21st. Six research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $9.00.

Institutional Investors Weigh In On Agenus

An institutional investor recently bought a new position in Agenus stock. Invesco Ltd. acquired a new position in Agenus Inc. (NASDAQ:AGEN) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 58,281 shares of the biotechnology company’s stock, valued at approximately $88,000. Invesco Ltd. owned approximately 0.28% of Agenus as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.